As demand grows for alternatives to costly GLP-1 therapies, AI-powered “digital twins” are emerging as a novel approach to managing chronic metabolic conditions such as diabetes and obesity. Startups like Twin Health are combining wearable sensor data with machine learning to create individualized metabolic models that guide real-time lifestyle interventions. By continuously analyzing biomarkers and behavioral inputs, these virtual replicas aim to support sustained weight loss and glycemic control without pharmacologic therapy. Early patient experiences suggest that personalized, data-driven recommendations may help overcome the limitations of traditional diet-based approaches, offering a scalable, non-drug pathway for long-term chronic disease management.
Author: Abhay Panchal
The U.S. healthcare system is approaching a tipping point, driven by three converging threats: rising care costs, a growing chronic disease burden, and a physician workforce trained for a rapidly outdated model of care. With national healthcare spending projected to surpass $7 trillion by the end of the decade, incremental policy fixes are unlikely to keep pace with mounting financial and clinical pressures. As chronic conditions like diabetes continue to drive long-term complications and high-cost care, prevention alone may not be sufficient to offset system-wide strain. In response, generative AI is emerging as a potential force multiplier—automating routine monitoring and…
New research presented at the 2026 Crohn’s & Colitis Congress® highlights a rapidly evolving therapeutic landscape in inflammatory bowel disease (IBD), spanning metabolic drugs, engineered microbiome therapies, and real-world treatment data. GLP-1 receptor agonists—commonly used for obesity and diabetes—were associated with improved IBD outcomes across independent cohorts, including reduced corticosteroid use, fewer hospitalizations, intestinal surgeries, and lower mortality, without increased surgical risk. These findings suggest potential benefits beyond metabolic disease and warrant further prospective evaluation in IBD populations. Researchers also introduced a next-generation live biotherapeutic for ulcerative colitis: a genetically engineered strain of E. coli Nissle 1917 designed to selectively…
Independent physician practices are facing mounting financial strain as operating costs rise faster than reimbursements, driving many toward consolidation with hospitals, insurers, or private equity firms. Lingering pandemic-related revenue drops, combined with increasing expenses tied to staffing, compliance, technology, and malpractice coverage, are further tightening cash flow across midsize practices. These pressures are reshaping how practices approach growth and financing. Traditional lenders are placing greater emphasis on predictable cash flow, EBITDA margins, accounts receivable timelines, and payer mix—factors that can significantly influence access to capital. In this environment, practices with inconsistent revenue cycles or heavy dependence on government payers may…
For years, gut health has been used liberally across research papers, probiotic marketing campaigns, and patient conversations—often without a consistent clinical definition. Now, a new 2026 consensus statement from the International Scientific Association for Probiotics and Prebiotics (ISAPP), published in Nature Reviews Gastroenterology & Hepatology, attempts to bring much-needed clarity to a term that sits at the intersection of microbiome science, GI physiology, and patient-reported outcomes. For gastroenterologists, the key shift is this: gut health is no longer defined solely by the absence of disease—but by the presence of normal GI function and the absence of symptoms that meaningfully impact…
Medical malpractice continues to be an occupational reality in gastroenterology. In fact, a landmark study by Jena et al. found that most gastroenterologists will face at least one lawsuit over the course of their careers. While many claims never result in financial penalties, the emotional toll, reputational risk, and time burden can be substantial. In GI practice, litigation is most often triggered by missed or delayed diagnoses, endoscopic complications—particularly during ERCP—perforations, and breakdowns in communication. And in today’s fast-paced clinical environment, opportunities to build rapport with patients are becoming increasingly limited. Workflows like open-access endoscopy and reliance on electronic medical…
Artificial intelligence is steadily moving from hype to hands-on utility in endoscopy suites. In this edition of Sharma’s Endoscopy Insights, two recent studies explore how AI could enhance both optical diagnosis and quality measurement during colonoscopy. The first study evaluated computer-aided diagnosis (CADx) in identifying sessile serrated lesions (SSLs)—a known blind spot in colorectal cancer prevention. Endoscopists demonstrated higher diagnostic accuracy when CADx supported optical classification, particularly in distinguishing SSLs from hyperplastic polyps. However, current systems still face limitations in reliably characterizing these lesions, highlighting the need for further refinement. The second study focused on withdrawal time, a key colonoscopy…
Despite the introduction of more specific ICD-10-CM codes for short bowel syndrome (SBS), new real-world U.S. claims data presented at ASPEN 2026 suggest that the majority of eligible patients may still be going uncounted. In an analysis led by Alan Buchman, MD, MSPH, researchers found that only 28% of the expected SBS population was captured using the updated, syndrome-specific codes—raising concerns around widespread undercoding and misclassification in clinical practice. Historically, SBS prevalence estimates have varied significantly due to reliance on broad diagnostic labels such as postoperative malabsorption, which fail to distinguish between patients with minimal resections and those with true…
A new population-based study published in Clinical Gastroenterology and Hepatology evaluated the real-world performance of a smartphone-based fecal immunochemical test (FIT) designed for at-home colorectal cancer (CRC) screening—no lab visit required. Conducted within Germany’s BLITZ screening cohort (2021–2023), the study compared a rapid stool test interpreted via smartphone camera with a conventional laboratory FIT among individuals scheduled for screening colonoscopy. More than half of participants (55%) opted to use the smartphone-based FIT, and 89% viewed it as a useful alternative to traditional lab-based testing. Among users, the digital FIT demonstrated comparable specificity (92%) and similar sensitivity for detecting advanced neoplasms…
The American Gastroenterological Association (AGA) has released updated practice guidance on Barrett’s esophagus (BE) surveillance, marking its first comprehensive update on post-diagnosis monitoring since 2011. Published in Gastroenterology, the guideline introduces eight evidence-based recommendations that shift BE surveillance away from a one-size-fits-all model toward a more individualized, risk-based approach. Notably, BE segment length is now recommended as a key determinant for guiding endoscopic surveillance intervals, while routine surveillance is no longer advised for patients with columnar-lined esophagus measuring less than 1 cm in the absence of dysplasia or visible lesions. The guidance also underscores the importance of reassessing surveillance based…